ID   DNJB2_HUMAN             Reviewed;         324 AA.
AC   P25686; A8K9P6; Q53QD7; Q8IUK1; Q8IUK2; Q96F52;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 3.
DT   28-JAN-2026, entry version 215.
DE   RecName: Full=DnaJ homolog subfamily B member 2 {ECO:0000305};
DE   AltName: Full=Heat shock 40 kDa protein 3 {ECO:0000312|MIM:604139};
DE   AltName: Full=Heat shock protein J1 {ECO:0000303|PubMed:1599432};
DE            Short=HSJ-1 {ECO:0000303|PubMed:1599432};
DE   Flags: Precursor;
GN   Name=DNAJB2 {ECO:0000312|HGNC:HGNC:5228};
GN   Synonyms=HSJ1 {ECO:0000303|PubMed:1599432}, HSPF3
GN   {ECO:0000312|MIM:604139};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=1599432; DOI=10.1042/bj2840469;
RA   Cheetham M.E., Brion J.-P., Anderton B.H.;
RT   "Human homologues of the bacterial heat-shock protein DnaJ are
RT   preferentially expressed in neurons.";
RL   Biochem. J. 284:469-476(1992).
RN   [2]
RP   SEQUENCE REVISION TO 214.
RA   Cheetham M.E.;
RL   Submitted (JUL-1998) to UniProtKB.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Lung;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Colon, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=7957263; DOI=10.1111/j.1432-1033.1994.tb20030.x;
RA   Cheetham M.E., Jackson A.P., Anderton B.H.;
RT   "Regulation of 70-kDa heat-shock-protein ATPase activity and substrate
RT   binding by human DnaJ-like proteins, HSJ1a and HSJ1b.";
RL   Eur. J. Biochem. 226:99-107(1994).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION (ISOFORMS 1 AND 2), TOPOLOGY (ISOFORM 1),
RP   TISSUE SPECIFICITY (ISOFORMS 1 AND 2), MUTAGENESIS OF HIS-31; CYS-321 AND
RP   LEU-324, ISOPRENYLATION AT CYS-321, METHYLATION AT CYS-321, AND MOTIF.
RX   PubMed=12754272; DOI=10.1074/jbc.m212349200;
RA   Chapple J.P., Cheetham M.E.;
RT   "The chaperone environment at the cytoplasmic face of the endoplasmic
RT   reticulum can modulate rhodopsin processing and inclusion formation.";
RL   J. Biol. Chem. 278:19087-19094(2003).
RN   [10]
RP   FUNCTION, INTERACTION WITH HSPA8 AND PSMA3, UBIQUITINATION BY STUB1,
RP   DOMAIN, AND MUTAGENESIS OF 31-HIS--ASP-33; SER-219; GLU-222; SER-262 AND
RP   GLU-265.
RX   PubMed=15936278; DOI=10.1016/j.cub.2005.04.058;
RA   Westhoff B., Chapple J.P., van der Spuy J., Hoehfeld J., Cheetham M.E.;
RT   "HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients
RT   to the proteasome.";
RL   Curr. Biol. 15:1058-1064(2005).
RN   [11]
RP   FUNCTION, DOMAIN, AND MUTAGENESIS OF HIS-31.
RX   PubMed=20889486; DOI=10.1093/hmg/ddq428;
RA   Rose J.M., Novoselov S.S., Robinson P.A., Cheetham M.E.;
RT   "Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain
RT   mutant.";
RL   Hum. Mol. Genet. 20:16-27(2011).
RN   [12]
RP   FUNCTION.
RX   PubMed=21719532; DOI=10.1210/me.2011-1020;
RA   Meimaridou E., Gooljar S.B., Ramnarace N., Anthonypillai L., Clark A.J.,
RA   Chapple J.P.;
RT   "The cytosolic chaperone Hsc70 promotes traffic to the cell surface of
RT   intracellular retained melanocortin-4 receptor mutants.";
RL   Mol. Endocrinol. 25:1650-1660(2011).
RN   [13]
RP   FUNCTION, INTERACTION WITH HSP70, SUBCELLULAR LOCATION, DOMAIN, AND
RP   MUTAGENESIS OF 31-HIS--ASP-33; SER-219; GLU-222; SER-262 AND GLU-265.
RX   PubMed=21625540; DOI=10.1371/journal.pone.0019763;
RA   Gao X.C., Zhou C.J., Zhou Z.R., Zhang Y.H., Zheng X.M., Song A.X., Hu H.Y.;
RT   "Co-chaperone HSJ1a dually regulates the proteasomal degradation of ataxin-
RT   3.";
RL   PLoS ONE 6:E19763-E19763(2011).
RN   [14]
RP   INVOLVEMENT IN HMNR5.
RX   PubMed=22522442; DOI=10.1002/ana.22684;
RA   Blumen S.C., Astord S., Robin V., Vignaud L., Toumi N., Cieslik A.,
RA   Achiron A., Carasso R.L., Gurevich M., Braverman I., Blumen N., Munich A.,
RA   Barkats M., Viollet L.;
RT   "A rare recessive distal hereditary motor neuropathy with HSJ1 chaperone
RT   mutation.";
RL   Ann. Neurol. 71:509-519(2012).
RN   [15]
RP   FUNCTION.
RX   PubMed=22396390; DOI=10.1093/brain/aws022;
RA   Labbadia J., Novoselov S.S., Bett J.S., Weiss A., Paganetti P., Bates G.P.,
RA   Cheetham M.E.;
RT   "Suppression of protein aggregation by chaperone modification of high
RT   molecular weight complexes.";
RL   Brain 135:1180-1196(2012).
RN   [16]
RP   FUNCTION.
RX   PubMed=24023695; DOI=10.1371/journal.pone.0073944;
RA   Novoselov S.S., Mustill W.J., Gray A.L., Dick J.R., Kanuga N., Kalmar B.,
RA   Greensmith L., Cheetham M.E.;
RT   "Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A)
RT   mouse model of amyotrophic lateral sclerosis.";
RL   PLoS ONE 8:E73944-E73944(2013).
RN   [17]
RP   INVOLVEMENT IN HMNR5, AND VARIANT HMNR5 CYS-5.
RX   PubMed=24627108; DOI=10.1007/s00415-014-7289-8;
RA   Schabhuettl M., Wieland T., Senderek J., Baets J., Timmerman V.,
RA   De Jonghe P., Reilly M.M., Stieglbauer K., Laich E., Windhager R., Erwa W.,
RA   Trajanoski S., Strom T.M., Auer-Grumbach M.;
RT   "Whole-exome sequencing in patients with inherited neuropathies: outcome
RT   and challenges.";
RL   J. Neurol. 261:970-982(2014).
RN   [18]
RP   INVOLVEMENT IN HMNR5, AND VARIANT HMNR5 CYS-5.
RX   PubMed=25274842; DOI=10.1212/wnl.0000000000000966;
RA   Gess B., Auer-Grumbach M., Schirmacher A., Strom T., Zitzelsberger M.,
RA   Rudnik-Schoneborn S., Rohr D., Halfter H., Young P., Senderek J.;
RT   "HSJ1-related hereditary neuropathies: novel mutations and extended
RT   clinical spectrum.";
RL   Neurology 83:1726-1732(2014).
RN   [19]
RP   STRUCTURE BY NMR OF 1-71, FUNCTION, INTERACTION WITH HSP70, AND DOMAIN.
RX   PubMed=22219199; DOI=10.1074/jbc.m111.294728;
RA   Gao X.C., Zhou C.J., Zhou Z.R., Wu M., Cao C.Y., Hu H.Y.;
RT   "The C-terminal helices of heat shock protein 70 are essential for J-domain
RT   binding and ATPase activation.";
RL   J. Biol. Chem. 287:6044-6052(2012).
CC   -!- FUNCTION: Functions as a co-chaperone, regulating the substrate binding
CC       and activating the ATPase activity of chaperones of the HSP70/heat
CC       shock protein 70 family (PubMed:22219199, PubMed:7957263). In parallel,
CC       also contributes to the ubiquitin-dependent proteasomal degradation of
CC       misfolded proteins (PubMed:15936278, PubMed:21625540). Thereby, may
CC       regulate the aggregation and promote the functional recovery of
CC       misfolded proteins like HTT, MC4R, PRKN, RHO and SOD1 and be crucial
CC       for many biological processes (PubMed:12754272, PubMed:20889486,
CC       PubMed:21719532, PubMed:22396390, PubMed:24023695). Isoform 1 which is
CC       localized to the endoplasmic reticulum membranes may specifically
CC       function in ER-associated protein degradation of misfolded proteins
CC       (PubMed:15936278). {ECO:0000269|PubMed:12754272,
CC       ECO:0000269|PubMed:15936278, ECO:0000269|PubMed:20889486,
CC       ECO:0000269|PubMed:21625540, ECO:0000269|PubMed:21719532,
CC       ECO:0000269|PubMed:22219199, ECO:0000269|PubMed:22396390,
CC       ECO:0000269|PubMed:24023695, ECO:0000269|PubMed:7957263}.
CC   -!- SUBUNIT: Interacts with HSP70 (HSPA1A or HSPA1B) (PubMed:21625540,
CC       PubMed:22219199). Interacts with HSPA8/Hsc70 (PubMed:15936278).
CC       Interacts with PSMA3 and most probably with the whole proteasomal
CC       complex (PubMed:15936278). {ECO:0000269|PubMed:15936278,
CC       ECO:0000269|PubMed:21625540, ECO:0000269|PubMed:22219199}.
CC   -!- INTERACTION:
CC       P25686; P58340: MLF1; NbExp=2; IntAct=EBI-6166532, EBI-721328;
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:12754272, ECO:0000269|PubMed:21625540}. Nucleus
CC       {ECO:0000269|PubMed:12754272}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:12754272}; Lipid-anchor
CC       {ECO:0000269|PubMed:12754272}; Cytoplasmic side
CC       {ECO:0000269|PubMed:12754272}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=HSJ1b {ECO:0000303|PubMed:1599432};
CC         IsoId=P25686-3; Sequence=Displayed;
CC       Name=2; Synonyms=HSJ1a {ECO:0000303|PubMed:1599432}, DNAJB2a
CC       {ECO:0000303|PubMed:20889486};
CC         IsoId=P25686-2; Sequence=VSP_001286, VSP_001287;
CC   -!- TISSUE SPECIFICITY: More abundantly expressed in neocortex, cerebellum,
CC       spinal cord and retina where it is expressed by neuronal cells (at
CC       protein level) (PubMed:12754272, PubMed:1599432). Detected at much
CC       lower level in non-neuronal tissues including kidney, lung, heart,
CC       skeletal muscle, spleen and testis (at protein level) (PubMed:12754272,
CC       PubMed:1599432). Isoform 1 is more abundant in neocortex and cerebellum
CC       compared to isoform 2 (at protein level) (PubMed:12754272).
CC       {ECO:0000269|PubMed:12754272, ECO:0000269|PubMed:1599432}.
CC   -!- DOMAIN: The J domain is sufficient to interact with HSP70 (HSPA1A or
CC       HSPA1B) and activate its ATPase activity (PubMed:22219199). The J
CC       domain is also required for the HSP70-mediated and ubiquitin-dependent
CC       proteasomal degradation of proteins like ATXN3 (PubMed:21625540). The J
CC       domain is required to reduce PRKN cytoplasmic aggregation
CC       (PubMed:20889486). {ECO:0000269|PubMed:20889486,
CC       ECO:0000269|PubMed:21625540, ECO:0000269|PubMed:22219199}.
CC   -!- DOMAIN: The UIM domains mediate interaction with ubiquitinated
CC       chaperone clients and with the proteasome (PubMed:15936278). The UIM
CC       domains may have an opposite activity to the J domain, binding
CC       ubiquitinated proteins and protecting them from HSP70-mediated
CC       proteasomal degradation (PubMed:21625540). The UIM domains are not
CC       required to reduce PRKN cytoplasmic aggregation (PubMed:20889486).
CC       {ECO:0000269|PubMed:15936278, ECO:0000269|PubMed:20889486,
CC       ECO:0000269|PubMed:21625540}.
CC   -!- PTM: Ubiquitinated by STUB1; does not lead to proteasomal degradation.
CC       {ECO:0000269|PubMed:15936278}.
CC   -!- DISEASE: Neuronopathy, distal hereditary motor, autosomal recessive 5
CC       (HMNR5) [MIM:614881]: A form of distal hereditary motor neuronopathy, a
CC       heterogeneous group of neuromuscular disorders caused by selective
CC       degeneration of motor neurons in the anterior horn of the spinal cord,
CC       without sensory deficit in the posterior horn. The overall clinical
CC       picture consists of a classical distal muscular atrophy syndrome in the
CC       legs without clinical sensory loss. The disease starts with weakness
CC       and wasting of distal muscles of the anterior tibial and peroneal
CC       compartments of the legs. Later on, weakness and atrophy may expand to
CC       the proximal muscles of the lower limbs and/or to the distal upper
CC       limbs. HMNR5 is characterized by young adult onset of slowly
CC       progressive distal muscle weakness and atrophy resulting in gait
CC       impairment and loss of reflexes. {ECO:0000269|PubMed:22522442,
CC       ECO:0000269|PubMed:24627108, ECO:0000269|PubMed:25274842}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA09035.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S37375; AAA09034.1; -; mRNA.
DR   EMBL; S37374; AAA09035.1; ALT_FRAME; mRNA.
DR   EMBL; X63368; CAA44968.2; -; Genomic_DNA.
DR   EMBL; X63368; CAA44969.2; -; Genomic_DNA.
DR   EMBL; BT007088; AAP35751.1; -; mRNA.
DR   EMBL; AK292761; BAF85450.1; -; mRNA.
DR   EMBL; AK312723; BAG35597.1; -; mRNA.
DR   EMBL; AC114803; AAY24037.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70722.1; -; Genomic_DNA.
DR   EMBL; BC011609; AAH11609.1; -; mRNA.
DR   EMBL; BC047056; AAH47056.1; -; mRNA.
DR   CCDS; CCDS2439.1; -. [P25686-3]
DR   CCDS; CCDS46519.1; -. [P25686-2]
DR   PIR; S23508; S23508.
DR   RefSeq; NP_001034639.1; NM_001039550.2. [P25686-2]
DR   RefSeq; NP_006727.2; NM_006736.5. [P25686-3]
DR   PDB; 2LGW; NMR; -; A=1-91.
DR   PDBsum; 2LGW; -.
DR   AlphaFoldDB; P25686; -.
DR   BMRB; P25686; -.
DR   SMR; P25686; -.
DR   BioGRID; 109533; 130.
DR   CORUM; P25686; -.
DR   DIP; DIP-29051N; -.
DR   FunCoup; P25686; 1988.
DR   IntAct; P25686; 110.
DR   MINT; P25686; -.
DR   STRING; 9606.ENSP00000338019; -.
DR   GlyCosmos; P25686; 1 site, 1 glycan.
DR   GlyGen; P25686; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P25686; -.
DR   PhosphoSitePlus; P25686; -.
DR   BioMuta; DNAJB2; -.
DR   DMDM; 158518384; -.
DR   jPOST; P25686; -.
DR   MassIVE; P25686; -.
DR   PaxDb; 9606-ENSP00000338019; -.
DR   PeptideAtlas; P25686; -.
DR   ProteomicsDB; 54281; -. [P25686-3]
DR   ProteomicsDB; 54282; -. [P25686-2]
DR   Pumba; P25686; -.
DR   Antibodypedia; 34321; 364 antibodies from 32 providers.
DR   DNASU; 3300; -.
DR   Ensembl; ENST00000336576.10; ENSP00000338019.5; ENSG00000135924.18. [P25686-3]
DR   Ensembl; ENST00000392086.8; ENSP00000375936.4; ENSG00000135924.18. [P25686-2]
DR   GeneID; 3300; -.
DR   KEGG; hsa:3300; -.
DR   MANE-Select; ENST00000336576.10; ENSP00000338019.5; NM_006736.6; NP_006727.2.
DR   UCSC; uc002vkw.2; human. [P25686-3]
DR   UCSC; uc002vkx.2; human.
DR   AGR; HGNC:5228; -.
DR   ClinPGx; PA27415; -.
DR   CTD; 3300; -.
DR   DisGeNET; 3300; -.
DR   GeneCards; DNAJB2; -.
DR   HGNC; HGNC:5228; DNAJB2.
DR   HPA; ENSG00000135924; Tissue enhanced (brain).
DR   MalaCards; DNAJB2; -.
DR   MIM; 604139; gene.
DR   MIM; 614881; phenotype.
DR   OpenTargets; ENSG00000135924; -.
DR   Orphanet; 443950; DNAJB2-related Charcot-Marie-Tooth disease type 2.
DR   Orphanet; 314485; Young adult-onset distal hereditary motor neuropathy.
DR   VEuPathDB; HostDB:ENSG00000135924; -.
DR   eggNOG; KOG0714; Eukaryota.
DR   GeneTree; ENSGT00940000160220; -.
DR   InParanoid; P25686; -.
DR   OMA; HHRAGVF; -.
DR   OrthoDB; 10250354at2759; -.
DR   PAN-GO; P25686; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; P25686; -.
DR   PathwayCommons; P25686; -.
DR   SignaLink; P25686; -.
DR   Agora; ENSG00000135924; -.
DR   BioGRID-ORCS; 3300; 24 hits in 1158 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; DNAJB2; human.
DR   EvolutionaryTrace; P25686; -.
DR   GeneWiki; DNAJB2; -.
DR   GenomeRNAi; 3300; -.
DR   Pharos; P25686; Tbio.
DR   PRO; PR:P25686; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P25686; protein.
DR   Bgee; ENSG00000135924; Expressed in C1 segment of cervical spinal cord and 201 other cell types or tissues.
DR   ExpressionAtlas; P25686; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0098554; C:cytoplasmic side of endoplasmic reticulum membrane; TAS:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016234; C:inclusion body; IDA:BHF-UCL.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0000502; C:proteasome complex; IDA:BHF-UCL.
DR   GO; GO:0001671; F:ATPase activator activity; IDA:UniProtKB.
DR   GO; GO:0030544; F:Hsp70 protein binding; IDA:UniProtKB.
DR   GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:0070628; F:proteasome binding; IDA:BHF-UCL.
DR   GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0140318; F:protein transporter activity; TAS:ARUK-UCL.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0140036; F:ubiquitin-modified protein reader activity; IDA:ARUK-UCL.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0036503; P:ERAD pathway; IDA:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IGI:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IGI:UniProtKB.
DR   GO; GO:0090084; P:negative regulation of inclusion body assembly; IDA:BHF-UCL.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:0090086; P:negative regulation of protein deubiquitination; IDA:BHF-UCL.
DR   GO; GO:0070050; P:neuron cellular homeostasis; TAS:ARUK-UCL.
DR   GO; GO:0032781; P:positive regulation of ATP-dependent activity; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IMP:UniProtKB.
DR   GO; GO:0042026; P:protein refolding; IDA:UniProtKB.
DR   GO; GO:1903332; P:regulation of protein folding; IDA:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IMP:UniProtKB.
DR   GO; GO:0006986; P:response to unfolded protein; TAS:ProtInc.
DR   CDD; cd06257; DnaJ; 1.
DR   FunFam; 1.10.287.110:FF:000021; DnaJ (Hsp40) homolog, subfamily B, member 2; 1.
DR   Gene3D; 6.10.140.100; -; 1.
DR   Gene3D; 1.10.287.110; DnaJ domain; 1.
DR   InterPro; IPR001623; DnaJ_domain.
DR   InterPro; IPR018253; DnaJ_domain_CS.
DR   InterPro; IPR043183; DNJB2/6-like.
DR   InterPro; IPR036869; J_dom_sf.
DR   InterPro; IPR003903; UIM_dom.
DR   PANTHER; PTHR45168; DNAJ HOMOLOG SUBFAMILY B MEMBER 2; 1.
DR   PANTHER; PTHR45168:SF1; DNAJ HOMOLOG SUBFAMILY B MEMBER 2; 1.
DR   Pfam; PF00226; DnaJ; 1.
DR   PRINTS; PR00625; JDOMAIN.
DR   SMART; SM00271; DnaJ; 1.
DR   SMART; SM00726; UIM; 2.
DR   SUPFAM; SSF46565; Chaperone J-domain; 1.
DR   PROSITE; PS00636; DNAJ_1; 1.
DR   PROSITE; PS50076; DNAJ_2; 1.
DR   PROSITE; PS50330; UIM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chaperone; Cytoplasm;
KW   Endoplasmic reticulum; Lipoprotein; Membrane; Methylation;
KW   Neurodegeneration; Neuropathy; Nucleus; Phosphoprotein; Prenylation;
KW   Proteomics identification; Reference proteome; Repeat; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYI5"
FT   CHAIN           2..321
FT                   /note="DnaJ homolog subfamily B member 2"
FT                   /id="PRO_0000071018"
FT   PROPEP          322..324
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000305|PubMed:12754272"
FT                   /id="PRO_0000438687"
FT   DOMAIN          2..71
FT                   /note="J"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00286"
FT   DOMAIN          210..226
FT                   /note="UIM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   DOMAIN          250..269
FT                   /note="UIM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   REGION          70..90
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          218..324
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           321..324
FT                   /note="CAAX motif"
FT                   /evidence="ECO:0000269|PubMed:12754272"
FT   COMPBIAS        224..241
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        280..289
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        303..324
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYI5"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYI5"
FT   MOD_RES         321
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000305|PubMed:12754272"
FT   LIPID           321
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12754272"
FT   VAR_SEQ         275..277
FT                   /note="GGR -> DVF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_001286"
FT   VAR_SEQ         278..324
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_001287"
FT   VARIANT         5
FT                   /note="Y -> C (in HMNR5; dbSNP:rs730882140)"
FT                   /evidence="ECO:0000269|PubMed:24627108,
FT                   ECO:0000269|PubMed:25274842"
FT                   /id="VAR_073286"
FT   VARIANT         270
FT                   /note="G -> R (in dbSNP:rs34127289)"
FT                   /id="VAR_048910"
FT   MUTAGEN         31..33
FT                   /note="HPD->QPN: Loss of interaction with HSP70 and loss of
FT                   the ability to promote ATXN3 proteasomal degradation."
FT                   /evidence="ECO:0000269|PubMed:21625540"
FT   MUTAGEN         31
FT                   /note="H->Q: Probable loss of interaction with HSP70 and
FT                   loss of the ability to reduce PRKN aggregation."
FT                   /evidence="ECO:0000269|PubMed:12754272,
FT                   ECO:0000269|PubMed:20889486"
FT   MUTAGEN         219
FT                   /note="S->A: Loss of interaction with polyubiquitin chains,
FT                   loss of interaction with PSMA3, and loss of the ability to
FT                   protect ATXN3 from proteasomal degradation; when associated
FT                   with A-222; A-262 and A-265."
FT                   /evidence="ECO:0000269|PubMed:15936278,
FT                   ECO:0000269|PubMed:21625540"
FT   MUTAGEN         222
FT                   /note="E->A: Loss of interaction with polyubiquitin chains,
FT                   loss of interaction with PSMA3, and loss of the ability to
FT                   protect ATXN3 from proteasomal degradation; when associated
FT                   with A-219; A-262 and A-265."
FT                   /evidence="ECO:0000269|PubMed:15936278,
FT                   ECO:0000269|PubMed:21625540"
FT   MUTAGEN         262
FT                   /note="S->A: Loss of interaction with polyubiquitin chains,
FT                   loss of interaction with PSMA3, and loss of the ability to
FT                   protect ATXN3 from proteasomal degradation; when associated
FT                   with A-219; A-222 and A-265."
FT                   /evidence="ECO:0000269|PubMed:15936278,
FT                   ECO:0000269|PubMed:21625540"
FT   MUTAGEN         265
FT                   /note="E->A: Loss of interaction with polyubiquitin chains,
FT                   loss of interaction with PSMA3, and loss of the ability to
FT                   protect ATXN3 from proteasomal degradation; when associated
FT                   with A-219; A-222 and A-262."
FT                   /evidence="ECO:0000269|PubMed:15936278,
FT                   ECO:0000269|PubMed:21625540"
FT   MUTAGEN         321
FT                   /note="C->S: Loss of localization to the endoplasmic
FT                   reticulum and relocalization to cytoplasm and nucleus."
FT                   /evidence="ECO:0000269|PubMed:12754272"
FT   MUTAGEN         324
FT                   /note="L->M: No effect on localization to the endoplasmic
FT                   reticulum membrane."
FT                   /evidence="ECO:0000269|PubMed:12754272"
FT   CONFLICT        214
FT                   /note="L -> R (in Ref. 1; AAA09034/AAA09035)"
FT                   /evidence="ECO:0000305"
FT   HELIX           4..7
FT                   /evidence="ECO:0007829|PDB:2LGW"
FT   STRAND          8..10
FT                   /evidence="ECO:0007829|PDB:2LGW"
FT   HELIX           16..29
FT                   /evidence="ECO:0007829|PDB:2LGW"
FT   TURN            32..34
FT                   /evidence="ECO:0007829|PDB:2LGW"
FT   HELIX           40..57
FT                   /evidence="ECO:0007829|PDB:2LGW"
FT   HELIX           59..70
FT                   /evidence="ECO:0007829|PDB:2LGW"
SQ   SEQUENCE   324 AA;  35580 MW;  0154ED3E29F34B4A CRC64;
     MASYYEILDV PRSASADDIK KAYRRKALQW HPDKNPDNKE FAEKKFKEVA EAYEVLSDKH
     KREIYDRYGR EGLTGTGTGP SRAEAGSGGP GFTFTFRSPE EVFREFFGSG DPFAELFDDL
     GPFSELQNRG SRHSGPFFTF SSSFPGHSDF SSSSFSFSPG AGAFRSVSTS TTFVQGRRIT
     TRRIMENGQE RVEVEEDGQL KSVTINGVPD DLALGLELSR REQQPSVTSR SGGTQVQQTP
     ASCPLDSDLS EDEDLQLAMA YSLSEMEAAG KKPAGGREAQ HRRQGRPKAQ HQDPGLGGTQ
     EGARGEATKR SPSPEEKASR CLIL
//
